Showing results (271-280 of 286) with videos related to

Sort By:
Pageof 29
Plos Medicine|March 19, 2024
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trialZoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Feasibility and impact of Lynch syndrome genetic testing in newly diagnosed colorectal cancer patients: a multicenter observational study in GreeceS Manolakou, N Tsoukalas, E Saloustros, et al.
Medrxiv : the Preprint Server for Health Sciences|December 16, 2022
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein VaccineGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
Science (New York, N.Y.)|July 4, 2015
Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeysDan H Barouch, Galit Alter, Thomas Broge, et al.
The Lancet. HIV|June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trialLinda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.
Medicine|February 13, 2016
The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled TrialWarren Dinges, Pierre-Marie Girard, Daniel Podzamczer, et al.
Eclinicalmedicine|November 8, 2023
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country studyGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
The Lancet. Respiratory Medicine|September 16, 2023
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trialGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
Eclinicalmedicine|August 3, 2023
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group studyGuy de Bruyn, Joyce Wang, Annie Purvis, et al.
The New England Journal of Medicine|May 4, 2022
Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 VaccineKaren J Hager, Gonzalo Pérez Marc, Philipe Gobeil, et al.
Pageof 29